Ivermectin as a Novel Therapy in COVID-19 Treatment

• Status: Completed
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Efficacy of Ivermectin in COVID-19 treatment

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Chloroquine; Doxycycline; Ivermectin

Criteria

Inclusion Criteria:

• All Adult Patients aging from 20 to 65 years-old with COVID-19 confirmed by pharyngeal swab PCR.

Exclusion Criteria:

• Allergy or contraindication to the drugs used in the study.

• Pregnant and lactating mothers.

• Patients with cardiac problems.